ARTICLE | Clinical News

Biogen reports Phase Ib extension data for aducanumab in AD

November 2, 2017 10:35 PM UTC

Biogen Inc. (NASDAQ:BIIB) reported 24- and 36-month data from a long-term extension of the Phase Ib PRIME trial to treat prodromal or mild Alzheimer’s disease showing that aducanumab (BIIB037) continued to reduce amyloid plaque levels, and, according to the company, suggest a continued benefit on the rate of cognitive decline, especially at the highest doses of aducanumab compared to patients who received placebo in the first year of the trial. The company presented the data at the Clinical Trials on Alzheimer’s Disease meeting in Boston.

Biogen was off $6.33 to $309.40 Thursday, as the data did little to change investors' view of aducanumab's risk/reward profile...